glycyrrhiz
acid
ga
triterpen
glycosid
found
root
licoric
plant
glycyrrhiza
glabra
ga
import
activ
ingredi
licoric
root
possess
wide
rang
pharmacolog
biolog
activ
ga
coupl
glycyrrhetin
acid
acid
develop
china
japan
antiinflammatori
antivir
antiallerg
drug
liver
diseas
review
summar
current
biolog
activ
ga
medic
applic
liver
diseas
pharmacolog
action
ga
includ
inhibit
hepat
apoptosi
necrosi
antiinflammatori
immun
regulatori
action
antivir
effect
antitumor
effect
paper
use
refer
physician
biologist
research
ga
open
door
novel
agent
drug
discoveri
develop
chines
herb
addit
research
ga
may
wide
use
treatment
liver
diseas
condit
applic
natur
compound
treatment
refractori
diseas
new
trend
modern
clinic
medicin
satisfactori
efficaci
clinic
low
toxic
natur
product
use
altern
treatment
mani
diseas
mani
hepatoprotect
monom
deriv
natur
herb
especi
china
glycyrrhiz
acid
ga
exampl
one
hepatoprotect
compound
tradit
chines
medicin
gancao
licoric
root
dri
root
glycyrrhiza
uralensi
fisch
licoric
g
inflata
bat
g
glabra
l
gancao
first
describ
chines
book
shen
nong
ben
cao
jing
ad
antidot
toxic
substanc
ach
diseas
gancao
complement
drug
reduc
toxic
increas
efficaci
tradit
use
gancao
involv
decoct
dri
plant
root
stem
possibl
therapeut
properti
gancao
includ
antiarthrit
antiallerg
antivir
antihepatotox
anticholinerg
antiestrogen
antiinflammatori
antileukemogen
anticarcinogen
effect
commonli
use
treatment
acut
chronic
liver
injuri
viral
hepat
hepat
steatosi
liver
fibrosi
hepatoma
viral
myocard
diseas
like
psoriasi
prostat
cancer
known
chemic
compon
gancao
includ
saponin
mainli
glycyrrhizin
ga
flavonoid
coumarin
alkaloid
polysaccharid
sitosterol
amino
acid
ga
figur
glycyrrhetin
acid
figur
wellcharacter
compon
gancao
ga
develop
hepatoprotect
drug
china
japan
ga
gener
glycyrrhetin
acid
metabol
process
human
bodi
therefor
pharmacolog
effect
ga
essenti
glycyrrhetin
acid
ga
also
call
glycyrrhizin
triterpen
glycosid
licoric
root
glycyrrhiza
glabra
consist
one
molecul
glycyrrhizin
consid
major
activ
compon
gancao
demonstr
studi
experiment
anim
model
clinic
studi
ga
use
clinic
year
patient
chronic
hepat
china
japan
show
satisfactori
therapeut
effect
mani
diseas
ga
also
wide
use
sweeten
flavor
agent
food
ga
main
substanc
licoric
one
import
substanc
util
tradit
medicin
almost
year
moreov
ga
report
antiallerg
antivir
antiinflammatori
activ
ga
also
found
suppress
rise
fast
blood
glucos
insulin
level
improv
glucos
toler
addit
ga
may
act
antidiabet
substanc
without
induc
side
effect
although
mechan
unclear
ga
form
two
epim
ga
ga
figur
ga
deriv
ga
isomer
theand
form
differ
c
h
tran
cisconfigur
respect
scholar
examin
distribut
characterist
rat
tissu
found
concentr
ga
liver
duodenum
significantli
higher
ga
iv
administr
howev
concentr
ga
tissu
lower
similar
ga
declin
rapidli
indic
protect
antiinflammatori
effect
ga
liver
may
better
ga
sever
clinic
studi
report
ga
efficaci
treatment
variou
type
inflamm
mainli
liver
tabl
also
lung
kidney
intestin
spinal
cord
common
use
ga
treatment
liver
diseas
ga
reduc
steatosi
necrosi
liver
cell
significantli
inhibit
interinterstiti
inflamm
liver
fibrosi
promot
cell
regener
ga
side
effect
therefor
consid
drug
worth
attent
promot
liver
diseas
tumor
necrosi
factoralpha
tnf
import
cytokin
key
mediat
hepat
apoptosi
necrosi
lpsdgaalninduc
liver
failur
plasma
tnflevel
also
elev
patient
chronic
hepat
caus
hepat
b
viral
acut
alcohol
hepat
therefor
tnfplay
key
role
pathogenesi
endotoxininduc
experiment
liver
injuri
also
mani
human
liver
diseas
activ
indic
almost
apoptosi
system
ga
antiinflammatori
antiapoptot
effect
via
suppress
tnfand
use
explain
hepatoprotect
effect
ga
tabl
ga
also
significantli
inhibit
releas
cytochrom
c
mitochondria
cytoplasm
antiinflammatori
activ
ga
may
reli
inhibit
releas
tnf
myeloperoxidas
activ
transloc
nuclear
factorb
nfb
nuclei
ga
also
upregul
express
prolifer
cell
nuclear
antigen
impli
might
abl
promot
regener
liver
injuri
activ
kupffer
cell
involv
ischemiareperfus
ir
induc
liver
injuri
highmobl
group
box
product
ga
shown
inhibit
product
kupffer
cell
prevent
irinduc
liver
injuri
ga
could
also
allevi
irinduc
spinal
cord
mechan
addit
ga
conjug
free
radic
might
explain
protect
action
ga
exampl
ga
effect
chemoprevent
agent
lead
acet
mediat
hepat
oxid
stress
rat
bind
lead
concanavalin
cona
induc
mous
model
ga
allevi
conainduc
inflamm
fibrosi
progress
liver
via
inhibit
cell
prolifer
respons
cona
via
jun
ntermin
kinas
jnk
extracellular
signalregul
kinas
erk
phosphoinositid
akt
pathway
regul
ga
suppress
tnfproduct
induc
lipid
moieti
lipopolysaccharid
lp
cell
inhibit
lipid
ainduc
nfb
activ
cell
express
tolllik
receptor
myeloid
differenti
cluster
differenti
bone
marrowderiv
macrophag
bmm
ga
also
inhibit
activ
mitogenactiv
protein
kinas
mapk
includ
jnk
protein
erk
bmm
addit
ga
inhibit
nfb
activ
product
induc
paclitaxel
nonbacteri
ligand
attenu
format
complex
result
inhibit
homodimer
therefor
ga
modul
complex
receptor
level
lead
suppress
lpsinduc
activ
signal
cascad
cytokin
product
indic
ga
attenu
inflammatori
respons
modul
innat
immun
respons
moreov
ga
prevent
activ
signal
transduc
activ
reduc
upregul
intercellular
cell
adhes
molecul
pselectin
express
reduc
format
poli
adenosin
diphosphateribos
par
nitrotyrosin
reduc
polymorphonuclear
neutrophil
pmn
infiltr
observ
suggest
broad
antiinflammatori
activ
ga
mediat
interact
lipid
bilay
therebi
attenu
receptor
mediat
signal
ga
inhibit
lytic
pathway
complement
system
may
prevent
tissu
injuri
caus
membran
attack
complex
therefor
ga
could
potent
agent
suppress
complementdepend
tissu
injuri
autoimmun
inflammatori
diseas
ga
suppress
system
inflammatori
respons
syndrom
sir
associ
antiinflammatori
respons
manifest
via
inhibit
cc
chemokin
ligand
product
pmn
may
also
potenti
inhibit
antiinflammatori
responseassoci
opportunist
infect
critic
ill
patient
sever
sir
also
studi
indic
antiinflammatori
mechan
ga
antivir
mechan
ga
mainli
includ
inhibit
viral
replic
immun
regul
ga
affect
cellular
signal
pathway
protein
kinas
c
casein
kinas
ii
transcript
factor
activ
protein
nfb
furthermor
nitrou
oxid
inhibit
replic
sever
virus
like
japanes
enceph
viru
member
flavivirida
famili
also
inhibit
ga
power
antiinflammatori
capabl
ga
make
effect
treatment
variou
type
hepat
like
viral
hepat
nonalcohol
hepat
ga
found
inhibit
replic
sarsassoci
viru
treatment
hcv
hepat
c
viru
infect
ga
inhibit
hcv
fulllength
viral
particl
hcv
core
gene
express
function
dosedepend
manner
synergist
effect
interferon
ga
also
involv
biliari
secret
excret
ga
increas
hepat
glutathion
level
inhibit
biliari
excret
glutathion
partli
inhibit
efflux
transport
locat
canalicular
membran
hepatocyt
transloc
glutathion
bilirubin
methotrex
mtx
glucuronid
eg
e
sulfat
conjug
organ
anion
hepatocyt
bile
canaliculu
ga
activ
certain
immun
function
ifn
product
augment
nk
cell
activ
modul
growth
respons
lymphocyt
via
augment
product
ga
enhanc
immun
function
applic
glycyrrhiz
acid
breakdown
product
glycyrrhetin
acid
manufactur
medica
treatment
inflammatori
bowel
diseas
applic
glycyrrhiz
acid
breakdown
product
glycyrrhetin
acid
manufactur
medica
treatment
inflammatori
bowel
diseas
ultrason
extract
method
chang
glycyrrhiz
acid
leach
phase
balanc
use
glycyrrhet
acid
andor
glycyrrhizin
produc
cosmet
prepar
tan
skin
use
glycyrrhetin
acid
glycyrrhiz
acid
relat
compound
prevent
andor
treatment
pulmonari
fibrosi
use
glycyrrhizin
deriv
product
inhibitor
use
glycyrrhizin
treatment
standard
therapyresist
hepat
c
patient
use
isoglycyrrhiz
acid
salt
thereof
treat
allerg
rhiniti
b
use
one
glycyrrhiz
acid
reduc
irrit
action
surfact
cosmet
composit
mice
ga
treatment
could
significantli
reduc
blood
immunoglobulin
e
ige
tnflevel
nitrou
oxid
synthas
no
activ
dosedepend
ga
could
also
enhanc
blood
immunoglobulin
iga
immunoglobulin
g
igg
immunoglobulin
igm
level
ar
mice
b
cell
respons
numer
patholog
process
cell
dysfunct
sever
trauma
major
surgeri
lead
increas
suscept
infect
cell
exercis
inhibitori
effect
product
ek
mediat
via
suppressor
molecul
ga
act
potent
inhibitor
cell
therefor
restor
level
restor
affect
cell
dysfunct
thermal
injur
mice
ga
regul
burnassoci
type
cell
respons
recov
make
unrespons
thu
restor
impair
cell
ga
act
promot
late
signal
transduct
lymphocyt
product
balanc
augment
suppress
effect
might
depend
level
stimul
stage
cell
therefor
determin
qualiti
quantiti
immunomodulatori
action
ga
blood
nasal
mucosa
ga
consumpt
decreas
antioxid
enzym
activ
lipid
peroxid
glutathion
level
level
enhanc
ifn
thu
protect
nasal
mucosa
oxid
injuri
improv
immun
activ
ga
interfer
virus
replic
virusinduc
proinflammatori
gene
express
includ
inhibit
virusinduc
format
reactiv
oxygen
speci
reduc
activ
nfb
jnk
redoxsensit
signal
event
known
relev
replic
effect
cyp
enzym
mainli
found
liver
bowel
wall
respons
bulk
phase
oxid
metabol
xenobiot
includ
dietari
toxin
carcinogen
mutagen
drug
administr
ga
abl
significantli
induc
cyp
content
reduc
incid
cancer
ga
also
protect
aflatoxininduc
oxid
stress
protect
effect
like
capac
inhibit
metabol
activ
hepatotoxin
critic
factor
pathogenesi
chemicalinduc
carcinogen
ocarboxymethyl
chitosan
nanoparticl
cmcnp
modifi
ga
variou
substitut
degre
effici
deliv
paclitaxel
ptx
hepatocellular
carcinoma
hcc
cmcnpga
significantli
facilit
increas
accumul
ptx
hepat
tumor
tissu
target
deliveri
ptx
hepatoma
carcinoma
cell
result
remark
enhanc
vitro
cytotox
vivo
antitumor
efficaci
diethylnitrosaminetr
experiment
anim
studi
chemoprevent
agent
hcc
modul
cell
prolifer
apoptosi
ga
may
associ
inhibit
hcc
therefor
ga
treatment
may
inhibit
occurr
hcc
activ
studi
show
ga
induct
effect
activ
therefor
clinician
pay
attent
drug
catalyz
especi
substrat
narrow
therapeut
rang
cyclosporin
avoid
possibl
clinic
signific
interact
ga
studi
reveal
area
concentrationtim
curv
mean
retent
time
methotrex
mtx
significantli
increas
ga
increas
advers
reaction
mtx
mtx
antifol
agent
anticanc
agent
immunosuppress
commonli
use
anticanc
chemotherapi
rheumatoid
arthriti
sever
psoriasi
advers
reaction
mtx
includ
nausea
vomit
diarrhea
hepatotox
case
report
show
combin
administr
ga
cilostazol
caus
pseudoaldosteron
therefor
concurr
use
ga
mtx
cilostazol
recommend
one
report
show
case
hypokalem
rhabdomyolysi
secondari
chronic
ga
intox
ga
ingest
could
therefor
potenti
aggrav
hypokalemia
patient
chronic
lax
abus
indic
use
ga
hypokalemia
treat
caution
ga
effect
combat
hyperglycemia
associ
patholog
complic
hyperlipidemia
abnorm
histoarchitectur
differ
organ
oxid
stress
includ
hemoglobininduc
ironmedi
free
radic
reaction
effect
ga
diabetesassoci
chang
almost
compar
glibenclamid
standard
antihyperglycem
drug
suggest
possibl
use
herbal
agent
drug
prevent
complic
diabet
mellitu
furthermor
ga
regul
renal
function
regul
water
channel
ga
administr
amelior
renal
concentr
abil
structur
lesion
renal
tissu
rat
earlyphas
ischemiaacut
renal
failur
reduct
inhibitor
ga
reduc
therapeut
loss
methylprednisolon
produc
methylprednisolon
sodium
larg
intestin
thu
improv
therapeut
properti
prodrug
inflammatori
bowel
diseas
ga
also
offer
protect
damag
induc
uvb
radiat
human
therefor
could
consid
promis
agent
addit
topic
formul
prevent
skin
cancer
ga
significantli
allevi
asthma
symptom
inhibit
lung
inflamm
reliev
acut
lung
injuri
directli
affect
cardiac
perform
play
role
myocardi
coronari
protect
presenc
cardiovascular
diseas
ga
may
prevent
brain
tissu
damag
put
therapeut
drug
neurodegen
diseas
associ
cognit
deficit
neuroinflamm
alzheim
diseas
could
suppress
ocular
hypertens
potenti
therapeut
effect
eye
diseas
ga
improv
resist
c
albican
infect
induc
cell
suppress
type
cytokin
product
cell
ga
inhibit
activ
macrophag
gener
stimul
neutrophil
regul
neutrophilassoci
gener
ga
may
provid
new
therapeut
strategi
could
influenc
outcom
certain
sever
infect
host
gener
drug
made
ga
market
mani
year
import
therapeut
use
magnesium
isoglycyrrhizin
inject
tianq
ganmei
chia
tai
tainq
jiangsu
china
one
exampl
drug
ga
magnesium
isoglycyrrhizin
effect
safe
treatment
chronic
liver
diseas
capabl
slow
progress
pulmonari
fibrosi
moreov
diammonium
glycyrrhizin
entericco
capsul
tianq
ganp
chia
tai
tainq
jiangsu
china
diammonium
glycyrrhizin
inject
ganlixin
chia
tai
tainq
jiangsu
china
use
acut
chronic
hepat
associ
elev
alanin
aminotransferas
stronger
neominophagen
c
snmc
minophagen
pharmaceut
tokyo
japan
often
use
treatment
chronic
liver
diseas
improv
liver
dysfunct
snmc
compound
ga
tablet
includ
ga
mg
glycin
acid
mg
lcystein
hydrochlorid
mg
snmc
antiinflammatori
antiallerg
steroidlik
anticomplementari
immunoregulatori
effect
ga
combin
matrin
mat
improv
liver
fibrosi
effect
evidenc
lower
level
collagen
hyaluron
acid
ha
laminin
ln
less
hepat
stellat
cell
hsc
prolifer
collagen
ha
level
secret
hsc
vitro
combin
therapi
compar
ga
mat
alon
ga
combin
mat
could
protect
liver
cell
inhibit
hepat
fibrosi
may
therefor
safe
effect
strategi
improv
hepat
fibrosi
anim
model
ga
combin
mat
reduc
mortal
acetaminophen
overdos
mice
attenu
acetaminopheninduc
hepatotox
reduc
number
area
ygt
posit
foci
thu
protect
liver
function
prevent
hcc
occur
addit
combin
ga
cyclosporin
effect
treatment
nonsever
aplast
anemia
glycyrrhetin
acid
acid
aglycon
ga
stimul
glucoseinduc
insulin
secret
isol
pancreat
islet
glycyrrhetin
acid
treatment
enhanc
plasma
insulin
level
reduc
level
gluconeogen
enzym
liver
pentacycl
triterpen
acid
numer
biolog
activ
includ
antiinflammatori
antivir
antiallerg
antitumor
prolif
effect
glycyrrhetin
acid
restrain
prolifer
skin
tumor
mice
human
breast
cancer
cell
induc
apoptosi
cancer
cell
mechan
apoptosi
might
via
increas
free
ca
level
cell
mizushina
et
al
demonstr
glycyrrhetin
acid
potent
inhibit
activ
mammalian
polymeras
includ
pol
glycyrrhetin
acid
also
reduc
tnfproduct
nfb
activ
suppress
mous
ear
inflamm
stimul
tissu
plasminogen
activ
therefor
glycyrrhetin
acid
could
antiinflammatori
agent
base
pol
inhibit
anoth
licoric
acid
deriv
glycyrrhet
acid
triterpen
structur
compound
capabl
bind
alter
proinflammatori
properti
inhibit
cyclooxygenas
cox
induct
glycyrrhet
acid
signific
antivir
activ
rotaviru
replic
vitro
studi
determin
whether
glycyrrhet
acid
attenu
rotaviru
replic
vivo
underway
although
exact
mechan
unclear
howev
report
show
glycyrrhet
acid
inhibit
nfb
activ
interpret
glycyrrhet
acidmedi
regul
inflammatori
respons
acid
also
inhibit
activ
tyrosin
prevent
melanin
growth
whiten
report
show
glycyrrhetin
acid
like
respons
amelior
dysfunct
glutam
transport
astrocyt
inhibit
protein
kinas
c
activ
might
relat
pharmacolog
efficaci
review
summar
efficaci
ga
liver
diseas
clinic
trial
mechan
action
vitro
vivo
studi
indic
ga
could
modul
variou
molecular
pathway
liver
diseas
numer
patent
drug
includ
ga
tabl
studi
describ
highlight
use
ga
novel
chemoprevent
agent
liver
injuri
expect
futur
studi
ga
help
defin
variou
molecular
mechan
target
inflamm
steatosi
present
number
multicent
larg
sampl
random
doubleblind
control
chemoprevent
clinic
trial
ga
limit
extens
clinic
research
warrant
evalu
safeti
chemoprevent
efficaci
ga
alon
combin
chemotherapi
agent
